- TTP – Spero Cataland (USA)
The underlying pathophysiology of acquired TTP will be briefly summarized to set the stage for the discussion on novel therapeutic approaches to the treatment of acquired TTP. We will also discuss recent research describing the development of long-term complications in patients with a prior history including neurocognitive and neuropsychologic complications.
- aHUS – genomics of diagnosis & management – Piers Blombery (Australia)
The genetic lesions that are known to cause atypical haemolytic uremic syndrome (aHUS) and various laboratory methods used to detect these changes. The implications of the identification of genetic lesions in diagnosis and management of patients with aHUS.
Supported by and unrestricted educational grant from Instrumentation Laboratory
Hematologists and other physicians that are involved in the initial and long-term care of patients diagnosed with acquired TTP. Consultant and training haematologists, nephrologist and molecular pathologists.
At the end of this Webinar, the participants will be able to:
- To be able to understand the pathophysiology of acquired TTP and its relevance to treatment
- To learn about novel, more targeted approaches to therapy of acquired TTP
- To be able to recognize the presence of long term complications from a prior diagnosis of TTP including neurocognitive changes, headaches, mood disorders, and vascular complications
- To better understand the appropriate long-term follow-up for TTP patients to be able to diagnose these long-term complications and assess the risk for relapse
- Understand the current diagnostic definitions and classification of aHUS and its limitations
- Understand the diversity of genetic lesions known to result in aHUS
- Understand the basic laboratory methodologies used to detect these changes and their strengths and limitations
- Understand the role detection of genetic lesions has in the diagnosis and management of aHUS
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:
Name | Company | Role |
Geoffrey Barnes, MD | Portola | Consulting |
Blue Cross Blue Shield of Michigan | Research | |
BMS/Pfizer | Research | |
Chris Ward, PhD | Bayer | Speaker |
Boehringer-Ingelheim | Speaker, Advisory Board | |
BMS/Pfizer | Speaker, Advisory Board | |
Sanofi-Aventis, Alexion | Speaker, Advisory Board | |
Yukio Ozaki | The Sysmex Corporation | Advisory Board |
Spero Cataland | Ablynx | Consultant |
Contact
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.